I Am Fatima’s Child
Catherine, Princess of Wales Visits The Royal Marsden to Advance Holistic Cancer Care
Joe Biden Raises Prostate Cancer Awareness, Urges Men to Discuss Screening With Their Doctors
Adam B. Weiner: Exercise Improved QoL For Patients on ADT For Prostate Cancer
Vanessa Kerry։ Honored to Have Been Appointed as the Director-General's Special Envoy for Health Resilience
100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond
The Flower Behind Vincristine: A Chance Discovery in Hematologic Cancer Therapy
New "Value Cube" Framework in Nature Medicine Seeks to Redefine Value in Global Oncology
Enter the Recurrence Score and clinical context to view the RS category and trial-aligned interpretation for early HR+/HER2- breast cancer.
This calculator is intended for ER/PR+ HER2- breast cancer only
TAILORx (Node-negative): Demonstrated that chemotherapy provides minimal to no benefit for most patients with RS 11-25. For patients ≤50 years, some benefit may be seen in RS 16-25.
RxPONDER (Node-positive, 1-3 nodes): Showed that postmenopausal patients with RS 0-25 did not benefit from chemotherapy. Premenopausal patients derived benefit regardless of RS.
RS Categories:
Low
0-10
Intermediate
11-25
High
26-100
Our calculators apply published formulas as precisely as we can. Even so, no formula captures every detail of a real patient. Use the result as one input to your own assessment, not the final word.
